March 12, 20260 citations

Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.

TPThi-Phuong-Thao Pham TVThanh-Truc Vo TNT. N. H. Nguyen

Key Result

Semaglutide favored major adverse cardiovascular events (MACE) and myocardial infarction (MI) reduction, while dulaglutide and tirzepatide supported stroke prevention.

Key Points

To evaluate the relative efficacy of next-generation incretin therapies for cardio-renal protection in type 2 diabetes.
Conducted a network meta-analysis of existing GLP-1 therapy studies
Comparative outcomes included major adverse cardiovascular events (MACE) and myocardial infarction (MI)
Examined effects on stroke prevention and albuminuria versus eGFR
Semaglutide showed greater efficacy in reducing MACE and MI
Dulaglutide and tirzepatide demonstrated benefits in stroke prevention
Albuminuria outcomes were more favorable compared to eGFR responses

Structured PICO

Do next-generation incretin therapies have differential effects on cardio-renal outcomes in patients with type 2 diabetes?

Population

Patients with Type 2 Diabetes

Intervention

Next-generation incretin therapies (GLP-1-based therapies including semaglutide, dulaglutide, and tirzepatide)

Outcome

Cardiovascular and renal outcomes (MACE, MI, stroke, albuminuria, eGFR)composite

Different GLP-1-based therapies may offer specific cardiovascular and renal benefits in type 2 diabetes, with semaglutide favoring MACE/MI reduction and dulaglutide/tirzepatide supporting stroke prevention.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Cardiovascular and renal benefits of GLP-1-based therapies are outcome-specific. Semaglutide favoured MACE/MI reduction, dulaglutide and tirzepatide supported stroke prevention, and albuminuria outcomes were more responsive than eGFR. Further long-term head-to-head trials are needed.

Ask AI

Helpful

Bookmark

View Full Paper